Vitiligo: (1) causes and treatments

Pharmaceutical Journal

Volumn 270, Issue 7242, 2003, Pages 440-442

  Roberts, Nerys ^a   Lesage, Marion ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CATALASE; CORTICOSTEROID; HYDROQUINONE; IMMUNOSUPPRESSIVE AGENT; METHOXSALEN; METHYLPREDNISOLONE; PHOTOSENSITIZING AGENT; PSORALEN; STEROID; TACROLIMUS;

CONTACT DERMATITIS; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG SAFETY; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; NOTE; OCHRONOSIS; ONSET AGE; PHOTOTHERAPY; PSYCHOLOGICAL ASPECT; PSYCHOTHERAPY; SKIN ATROPHY; SKIN CANCER; SKIN DISEASE; SKIN PIGMENTATION; SKIN TRANSPLANTATION; SOCIAL ASPECT; VITILIGO;

EID: 0037472010     PISSN: 00316873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (5)

1. Nath SK, Majumder PP, Nordlund JJ. Genetic epidemiology of vitiligo: multilocus reccessivity cross-validated. Am J Hum Genet 1994;55:981-90.
2. Alkhateeb A, Stetler GL, Old W, Talbert J, Uhlhorn C, Taylor M et al. Mapping of an autoimmunity susceptibility locus (AIS1) to chromosome 1p31.3-p32.3. Hum Mol Genet 2002;11:661-7.
3. Papadopoulos L, Bor R. Psychological approaches to dermatology. Leicester: British Psychological Society Books; 1999.
4. Al'Abadie MS, Senior HJ, Bleehen SS, Gawkrodger DJ. Neuropeptide and neuronal marker studies in vitiligo. Br J Dermatol 1994;131:160-5.
5. Liu PY, Bondesson L, Lontz W, Johansson O. The occurence of cutaneous nerve endings and neuropeptides in vitiligo vulgaris: a case-control study. Arch Dermatol Res 1996;11:670-5.